Browse drugs

…s and the need for non-invasive respiratory support.Conclusions Nirsevimab prophylaxis was associated with reduced hospitalisation and sev…

…borative network and academic conferences. The effectiveness of nirsevimab will be assessed by a test-negative study design, and a two-sta…

…cient compared with the standard of practice (administration of palivizumab in eligible infants and no intervention in all other).Methods A…

…l budget savings and broader prophylaxis coverage compared with palivizumab. Its single-dose schedule demonstrates greater economic efficie…

…Background The long-acting monoclonal antibody nirsevimab and respiratory syncytial virus (RSV) vaccines became available…

…ogramme in the Mid-West region, nearly 90% of newborns received nirsevimab before discharge. Uptake was consistently high across months, i…

…ption In 2023, Respiratory Syncytial Virus (RSV) immunizations (Nirsevimab for infants and Abrysvo for pregnant mothers) were recommended …

…accine10 11(in the US in 2014 and 2019) and fatal outcomes from muscle relaxant used as a diluent for vaccine preparation (in Syria in 2014 and…

…Nirsevimab, a long-acting monoclonal antibody, was introduced last season …

… with a single injection of the long acting monoclonal antibody nirsevimab.…